The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index
Abstract
A proteolytically activatable EGFR Probody demonstrates antitumor efficacy while alleviating toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
ErbB receptors and signaling pathways in cancer
Hynes, N. E., & MacDonald, G. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.010 · Cited by 956
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
Baselga, J., & Arteaga, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.890 · Cited by 725
Cutaneous Adverse Effects With HER1/EGFR-Targeted Agents: Is There a Silver Lining?
Peréz-Soler, R., & Saltz, L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.6916 · Cited by 486
Marketed therapeutic antibodies compendium
Reichert, J. M. (2012) · mAbs · doi:10.4161/mabs.19931 · Cited by 368
Regales, L., Gong, Y., Shen, R., de Stanchina, E., Vivanco, I., Goel, A., Koutcher, J. A., Spassova, M., Ouerfelli, O., Mellinghoff, I. K., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38746 · Cited by 368
Liu, C., Sun, C., Huang, H., Janda, K. D., & Edgington, T. S. (2003) · PubMed · Cited by 334
The urokinase plasminogen activator system: a target for anti-cancer therapy
Ulisse, S., Baldini, E., Sorrenti, S., & D'Armiento, M. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909787314002 · Cited by 312
The Effects of Cetuximab Alone and in Combination With Radiation and/or Chemotherapy in Lung Cancer
Raben, D., Helfrich, B., Chan, D. C., Ciardiello, F., Zhao, L., Franklin, W., Barón, A. E., Zeng, C., Johnson, T. K., & Bunn, P. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.795.11.2 · Cited by 244
Riechelmann, H., Sauter, A., Golze, W., Hanft, G., Schroen, C., Hoermann, K., Erhardt, T., & Gronau, S. (2008) · Oral Oncology · doi:10.1016/j.oraloncology.2007.10.009 · Cited by 198
Matriptase and its putative role in cancer
Uhland, K. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6298-x · Cited by 186
Inflammation, proteases and cancer
van Kempen, L. C. L., de Visser, K. E., & Coussens, L. M. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.004 · Cited by 177
Modjtahedi, H., & Essapen, S. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3283330590 · Cited by 175
Antibody-Drug Conjugate Targets
Teicher, B. A. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909790192365 · Cited by 142
Cutsem, E. V., Tejpar, S., Vanbeckevoort, D., Peeters, M., Humblet, Y., Gelderblom, H. A. J., Vermorken, J. B., Viret, F., Glimelius, B. L. G., Gallerani, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.9243 · Cited by 134
Janjigian, Y. Y., Azzoli, C. G., Krug, L. M., Pereira, L. K., Rizvi, N. A., Pietanza, M. C., Kris, M. G., Ginsberg, M. S., Pao, W. J., Miller, V. A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2662 · Cited by 130
Rice, J. J., Schohn, A., Bessette, P. H., Boulware, K. T., & Daugherty, P. S. (2006) · Protein Science · doi:10.1110/ps.051897806 · Cited by 117
Self-citationSite-specific targeting of antibody activity in vivo mediated by disease-associated proteases
Erster, O., Thomas, J. M., Hamzah, J., Jabaiah, A. M., Getz, J. A., Schoep, T. D., Hall, S. S., Ruoslahti, E. I., & Daugherty, P. S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.035 · Cited by 71
Self-citationState of the Art in Tumor Antigen and Biomarker Discovery
Even-Desrumeaux, K., Baty, D., & Chames, P. (2011) · Cancers · doi:10.3390/cancers3022554 · Cited by 52
Imaging a functional tumorigenic biomarker in the transformed epithelium
LeBeau, A. M., Lee, M., Murphy, S. T., Hann, B. C., Warren, R. S., Santos, R. D., Kurhanewicz, J. V., Hanash, S., VanBrocklin, H. F., & Craik, C. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218694110 · Cited by 50
Cavazzoni, A., Alfieri, R. R., Cretella, D., Saccani, F., Ampollini, L., Galetti, M., Quaini, F., Graiani, G., Madeddu, D., Mozzoni, P., et al. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-91 · Cited by 44
Cited by
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery
Tang, L., Zheng, Y., Melo, M. B., Mabardi, L., Castaño, A. P., Xie, Y.-Q., Li, N., Kudchodkar, S. B., Wong, H. C., Jeng, E. K., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4181 · Cited by 660
Exploring the next generation of antibody–drug conjugates
Tsuchikama, K., Anami, Y., Ha, S. Y. Y., & Yamazaki, C. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00850-2 · Cited by 659
“In an early study 153 , investigators identified a cleavable peptide sequence (LSGRSDNH) sensitive to multiple proteases that are known to be minimally active in nonmalignant tissues but upregulated in the TME of various human cancers, including urokinase-type plasminogen activator 160 ,…”
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Metadata
- Authors
- Desnoyers, L. R., Vasiljeva, O., Richardson, J. H., Yang, A., Menendez, E. E. M., Liang, T. W., Wong, C., Bessette, P. H., Kamath, K., Moore, S. J., Sagert, J. G., Hostetter, D. R., Han, F., Gee, J., Flandez, J., Markham, K., Nguyen, M., Krimm, M., Wong, K. R., Liu, S., Daugherty, P. S., West, J. W., & Lowman, H. B.
- Venue
- Science Translational Medicine
- Published
- 2013-10-16
- Volume
- 5
- Issue
- 207
- Pages
- 207ra144-207ra144
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2106071154
- Cited by
- 281
- References
- 25
- FWCI
- 7.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.